Kornimate/medical-research-clean huggingface dataset:
induction of migraine attacks with aura using calcitonin gene-related peptide

Conditions: Migraine Aura; Migraine With Aura

Summary: calcitonin gene-related peptide (cgrp) is a key neuropeptide in migraine pathophysiology and treatment. this study investigates whether cgrp administration can trigger aura in individuals with a diagnosis of migraine with aura.

recent open-label findings show that calcitonin gene-related peptide (cgrp), a key player in migraine, can trigger aura attacks-despite its limited ability to cross the blood-brain barrier. this suggests cgrp might induce migraine aura via trigeminovascular activation, the same pathway involved in migraine headache. if confirmed, this could reshape treatment strategies for patients diagnosed with migraine with aura. to validate this effect and rule out nocebo influence, a randomized, double-blind, placebo-controlled trial is essential. its outcomes could inform future therapies targeting the migraine-aura connection.

Eligibility criteria:
inclusion criteria: * age 18 to 65 years of age upon entry into screening * history of migraine with aura for ≥ 12 months according to the international classification of headache disorders 3rd edition (ichd-3) criteria * ≥ 1 monthly day with aura that meets criteria as aura on average across the three months before screening * provision of informed consent prior to initiation of any study-specific activities/procedures. exclusion criteria: * any history of a primary or secondary headache disorder other than migraine without aura, migraine with aura, chronic migraine, and episodic tension-type headache * history or evidence of any other clinically significant disorder, condition, or disease (except for those outlined above) that, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion * the subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior * female subjects of childbearing potential with a positive pregnancy test during any study visit * cardiovascular disease of any kind, including cerebrovascular diseases * hypertension (systolic blood pressure of ≥150 mmhg and/or diastolic blood pressure of ≥100 mmhg) prior to the start of infusion on the experimental day * hypotension (systolic blood pressure of ≤90 mmhg and/or diastolic blood pressure of ≤50 mmhg) * initiation, discontinuation, or change of dosing of prophylactic medications within 2 months prior to study inclusion * intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start * headache of any intensity within 48 hours of infusion start * aura within 48 hours of infusion start

Keywords: migraine aura calcitonin gene-related peptide
pilot study to assess disease stability in a natalizumab to dimethyl fumarate crossover design

Conditions: Relapsing Remitting Multiple Sclerosis

Summary: this study will observe participants with relapsing remitting multiple sclerosis who are switching therapies from natalizumab to dimethyl fumarate to determine disease stability.

this is an investigator initiated, single site, open-label, single arm observational study examining the initial efficacy and tolerability of dimethyl fumarate in a real world clinical setting for patients with a relapsing form of multiple sclerosis (ms) when crossed over from natalizumab therapy. the decision to cross over from natalizumab to dmf will be made by the patient and the prescribing physician and must precede enrollment in the study. ms disease status and history will be gathered from the patient's medical records. patients will be followed for the first 24 weeks of their transition from natalizumab. assessments will be performed at baseline and every 4 weeks thereafter for 24 weeks. these assessments may include: * expanded disability status scale (edss) * relapse assessment * patient reported outcomes (pro) including quality of life, fatigue, and cognition outcome measures * magnetic resonance imaging (mri) * laboratory testing study drop outs due to dmf intolerability or other etiologies will be encouraged to complete the trial even if placed on alternative therapies.

Eligibility criteria:
inclusion criteria: 1. jcv indec of 1.5 of greater and currently receiving natalizumab therapy for at least 24 months 2. decision to treat with dmf must precede enrollment 3. ability to understand the purpose and risk of the study and provide authorization for the use of protected health information in accordance with the monitoring agency 4. men or women \>= 18 years at time of informed consent 5. naive to dmf or fumaric acid esters 6. confirmed diagnosis of a relapsing form of ms as verified by their treating physician exclusion criteria: 1. inability ot comply with study requirements as outlined in the informed consent 2. known active malignancies or any other major co morbidity that, in the opinion of the investigator, would affect the outcome of the study 3. pregnancy or breastfeeding 4. previous treatment with dimethyl fumarate

Keywords: relapsing multiple sclerosis dimethyl fumarate natalizumab
postoperative imrt combined with capecitabine for advanced gastric cancer patients

Conditions: Gastric Cancer

Summary: radiation therapy plus concurrent chemotherapy has been demonstrated a significant improvement in overall and disease-free survival according to intergroup trial 0116 in patients with gastric cancer after surgical complete resection. advantage of application of imrt has been shown in planning comparison studies for postoperative gastric patients. so the investigators designed the trial to see safety and efficacy of postoperative concurrent chemoradiotherapy of capecitabine combined with imrt for stage ii/ii gastric cancer.

in intergroup 0116, only 64% patients in concurrent chemoradiation group completed treatment as planed, but in recently reported artist trial, capecitabine was admitted to concurrent with radiotherapy,patients who completed treatment as planed in concurrent group reach high as 80%. imrt is an advanced radiotherapy technology which allows high conformal dose distribution to planing tumor volume (ptv) and low dose to organ at risk. the purpose of this study is to evaluate feasibility and efficacy of concurrent imrt combined with capecitabine for the treatment of gastric cancer patients after d1/2 surgery.

Eligibility criteria:
inclusion criteria: 1. postoperative histologically confirmed advanced adenocarcinoma of the stomach or the gastroesophageal junction. 2. age of 18 to 75, karnofsky score higher than 70. 3. postoperative histologically conformed metastasis in perigastric lymph nodes and/or tumor invasion to muscularis propria or subserosa, without positive incisal margin. stage ii/iii(ajcc 7th). 4. no severe functional damage of major organ, normal blood cell, normal liver and kidney function. 5. no clinical findings of distant metastasis. 6. predictive survival time longer than 6 months. - exclusion criteria: 1. peritoneal carcinomatosis, as diagnosed by mandatory laparoscopy or distant metastasis 2. concurrent treatment with other experimental drugs or other anti-cancer therapy, or treatment within a clinical trial within 30 days prior to trial entry 3. severe or uncontrolled cardiovascular disease (congestive heart failure nyha iii or iv, no myocardial infarction within the last 12 months, unstable angina pectoris, or significant arrhythmia) 4. active or uncontrolled infection. 5. definitive contraindications for the use of corticosteroids as premedication 6. prior systemic (chemo- or targeted) treatment. prior radiotherapy to the upper abdomen 7. any contraindication to treatment with cetuximab, capecitabine or cisplatin 8. previous malignancy within 5 years, with the exception of adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer 9. known hypersensitivity against any of the study drugs ( capecitabine)

Keywords: gastric cancer radiation chemotherapy
use of monoclonal antibodies for the treatment of mild to moderate covid-19 in non-hospitalized setting

Conditions: Covid19

Summary: no therapeutic agent is currently approved for the treatment of sarscov-2 infection. more importantly, no intervention is currently available to mitigate the progression of disease from mid/moderate to serve particularly in high risk patients. recognizing this limitation and urgency of finding a treatment for covid-19, the u.s. food and drug administration (fda) has issued an emergency use authorization (eua) to permit the emergencyuse of the unapproved product bamlanivimab or casirivimab + imdevimab for the treatment of mild to moderate coronavirus disease 2019 (covid19) in adults and pediatric patients with positive results of direct sars-cov-2 viral testing who are 12 years of age and older weighing at least 40 kg, and who are at high risk for progressing to severe covid-19 and/or hospitalization.


Eligibility criteria:
inclusion criteria: 1. adults and pediatric patients with positive results of direct sars-cov-2 viral testing 2. 12 years of age and older weighing at least 40 kg 3. are at ":high risk" for progressing to severe covid-19 and/or hospitalization high risk is defined as patients who meet at least one of the following criteria: 1. have a body mass index (bmi) \>35 2. have chronic kidney disease 3. have diabetes 4. have immunosuppressive disease 5. are currently receiving immunosuppressive treatment 6. are over 65 years of age 7. are over 55 years of age and have: cardiovascular disease, or hypertension, or chronic obstructive pulmonary disease/other chronic respiratory disease 8. are 12 - 17 years of age and have 9. bmi \>85th percentile for their age and gender based on cdc o growth charts, ii. sickle cell disease or iii. congenital or acquired heart disease or iv. neurodevelopmental disorders, for example, cerebral palsy, or a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to covid-19), or v. asthma, reactive airway or other chronic respiratory disease o that requires daily medication for control. exclusion criteria 1. younger than 12 years of age 2. do not meet criteria to be classified as "high risk'
the association of omentin and ischemic stroke

Conditions: Stroke; Brain Ischemia; Adipokines; Mutation

Summary: this observational study aims to research whether there is a relationship between omentin and ischemic stroke on the aspects of incidence, severity, and recovery etc.

to study the possible relationship between omentin and ischemic stroke, we intend to recruit the newly found acute ischemic stroke patients and patients without any stroke history and analysis the difference of plasma omentin level and the itln, which is the gene symbol of omentin.

Eligibility criteria:
inclusion criteria: * for ischemic stroke group,acute clinically defined ischemic stroke * for control group, without any history of stroke exclusion criteria: for ischemic stroke group * hemorrhagic stroke * previous ischemic stroke for control group * the expected life expense less than 3 years

Keywords: ischemic stroke omentin
walking and balance related to sagittal spinal posture alignment

Conditions: Hyperkyphosis; Walking, Difficulty; Balance; Distorted; Spinal Disease; Osteoporosis; Spine Degeneration

Summary: this study aims to improve understanding of the relationship between spinal alignment and walking and balance in people who have degenerative spinal conditions.

this prospective cohort study will include people who are attending physiotherapy to address a degenerative spinal condition and measure them longitudinally. the investigators will measure spinal alignment, walking capacity and pattern, dynamic balance, and back muscle strength along with self-reported measures that reflect the person's functional self-efficacy, quality of life, and general health. physical and self-reported outcome measures will be assessed at baseline before the physiotherapy-led exercise class commences, after completion at 6 weeks, and 6 months post baseline.

Eligibility criteria:
inclusion criteria: * participant is diagnosed with a degenerative spinal condition. * participant is willing and able to give informed consent for participation in the study. * men and women aged 18 years or older. * participant is able to understand and participate safely in a physiotherapy measurement assessment. * participant is enrolled in physiotherapy. exclusion criteria: * participant is unable to stand independently. * participant has a neurological condition which alters motor function and/or postural control.
treatment of chronic hand eczema with oral roflumilast (hero)

Conditions: Chronic Hand Eczema

Summary: this study is a multicentre, double-blinded, randomized, placebo-controlled, clinical trial with open-label extension. the purpose and aim of this study is to investigate the efficacy and safety of roflumilast (pde4-inhibitor) in adult patients with chronic hand eczema (che). patients will receive 16-week treatment with either roflumilast or placebo tablets. hereafter, both groups continue in open-label treatment for 12 weeks where both groups will receive treatment with roflumilast.

this study will investigate the efficacy and safety of roflumilast in adult patients with che and it is hypothesized that patients treated with oral roflumilast (500 microgram once daily) will experience an improvement in their moderate-to-severe che (measured by hand eczema severity index (hecsi)) and alter the skin microbiome. secondly, it is hypothesized that patients treated with oral roflumilast will experience improved lung function and weight loss. this study includes two phases: phase 1: 20 patients will receive 500 microgram tablet of roflumilast once daily for 16 weeks while 20 patients will receive placebo once daily for 16 weeks. phase 2: all 40 patients from phase 1 will receive 500 microgram tablet of roflumilast once daily for 12 weeks.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * age ≤ 75 years * hecsi ≥ 18 (moderate to severe hand eczema) * iga-che ≥ 3 * body mass index (bmi) ≥ 20 kg/m2 * negative pregnancy test (only women of child-bearing potential (see section 2.8)) * willing to use safe anticonception during entire study and at least 1 week after end of treatment (-5 times plasma half-life of roflumilast). this only account for women child-bearing potential * speaks, understands, and reads danish. exclusion criteria: * severe immunological disease, e.g. hiv, systemic lupus, and systemic sclerosis * diagnosis of current tuberculosis * current viral hepatitis * history of heart failure (nyha iii-iv) * history of moderate or severe liver failure (child-pugh b-c) * current or former depression with suicidal ideation * topical therapy (anti-inflammatory) for chronic hand eczema 14 days before randomization * topical therapy (anti-inflammatory) for chronic hand eczema during study * systemic therapy for chronic hand eczema 28 days before randomization * systemic therapy for chronic hand eczema during study * current treatment with oral dicloxacillin or macrolide * current treatment with topical antibiotics * diagnosis of contact eczema of clinical significance 3 months before randomization * previous treatment with apremilast (otezla®) or roflumilast (daxas®) * confirmed pregnancy * breast feeding * blood donation during study * allergy to roflumilast or any other pde-4 inhibitor
effects of sarcopenia on general health status in elderly: a population-based study

Conditions: Sarcopenia; Sarcopenic Obesity; Frailty

Summary: this is a observational study, that aimed to determine the prevalence of sarcopenia using european wording group on sarcopenia in older people (ewgsop) algorithm in a general elderly population in algarve region (portugal). because muscle is metabolically active tissue, sarcopenia may also contribute to the development of some of the metabolic disorders associated with aging. however, the risk factors associated with sarcopenia are poorly understood. thus, a cross-sectional survey of a sample of 274 elderly adults aged 60 or over, were included in the study. correlations of sarcopenia with functional level, lipid and glycemic profile, nutritional and physical activity level, fall risk, quality of life, and self-reported comorbidities will be studied.


Eligibility criteria:
inclusion criteria: * minimum age of 60 years; * live in the community; * independet gait. exclusion criteria: * presence of moderate or severe cognitive impairment; * presence of uncontrolled cardiovascular disease and active cancer; * use of a pacemaker; * use of internal prosthesis.

Keywords: sarcopenia quality of life frailty muscle strength aging body composition postural balance falls
social determinants of health screening and interventions

Conditions: Social Determinants of Health; Patient Satisfaction; Quality of Life

Summary: the primary objective of this study is to connect patients with community resources to improve social determinants of health. secondary objectives are improving patient satisfaction within the trauma and general surgery service, enhancement of physician-patient communication, betterment of surgery department hospital consumer assessment of healthcare providers and systems scores, and increased understanding of correlations between patient satisfaction and social determinants of health. the investigators hypothesize that (1) directed screening and intervention can have a positive effect for patients and hospitals, (2) directed patient advocacy will have an effect on patients' perception of care, (2) social determinants of health will have an effect on patients' perception of care, and (4) traumatic injury and acute surgery will have an effect on patients' perception of care.

the investigators will be conducting this study as a prospective, non-randomized quality improvement study that will look at patients 18 years of age and older who are admitted under the trauma and general surgery specialties. patients will be identified through admission to the trauma or general surgery service or referred to surgery services. eligible patients will be identified and approached by the study team. once the informed consent is completed, patients will be given a social determinants of health screening tool, an hospital consumer assessment of healthcare providers and systems feedback tool, and an short form health survey (sf-12) quality of life questionnaire. feedback from the hospital consumer assessment of healthcare providers and systems results will be given immediately to the relevant teams (nurses, doctors, etc.) to address the patient's concerns. prior to discharge, the patients will also be given referrals to designated community resources. on day 15 (+/- 7 days) after discharge, the patients will receive a follow up phone call where they will be asked if they have utilized the social determinants of health referrals. participants will also be given a second hospital consumer assessment of healthcare providers and systems feedback survey at this time. on day 30 (+/- 7 days) after discharge, the patients will receive a follow up phone call where the participants will be asked if they utilized the social determinants of health referrals. participants will also be given a second short form health survey (sf-12) quality of life survey at this time.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * admitted to the trauma or general surgery services * live within lucas county (for county referrals) * patient or legally authorized representative agrees to participate and is willing to sign informed consent exclusion criteria: * anyone less than 18 years old * any patient or legally authorized representative unwilling to sign informed consent * anyone who lives outside of lucas county or expresses unwillingness to use referral services
acupuncture for unintentional weight loss and anorexia with gi cancer

Conditions: Malignant Neoplasm of Gastrointestinal Tract

Summary: patients with cancer often experience appetite loss and weight loss unintentionally. rapid weight loss negatively impact on physical functioning, quality of life, and overall survival. patients will be randomly assigned into two groups. an intervention with acupuncture may slow down or stop the progression of cancer-related anorexia and weight loss.

the purpose of this research study is to investigate if acupuncture helps to improve appetite and slow down unintentional weight loss. the participants will be randomly divided into two groups and receive 8 sessions of acupuncture (two groups will receive different acupuncture points) for 8 weeks. during the study period, participants will be asked various questions about appetite, physical functioning, cancer-related symptoms and quality of life to understand changes related to body weight, as well as blood samples. the research team members will collect data regarding changes in appetite, body weight, body composition, and physical functioning.

Eligibility criteria:
inclusion criteria: * 21 year or older * medical diagnosis of gastrointestinal cancer (for example, gastric, biliary, or colorectal) * experienced weight loss of at least 5% over the last 6 months * ability to communicate in english * ability to follow the research protocol exclusion criteria: * plan to have surgical procedures at the time of recruitment * receive radiation therapy alone or in addition to chemotherapy during the study period * undergo surgery during the study or in the months prior to the study * no plan to have chemotherapy after the surgery * any comorbidities that may affect the interpretation of study findings * open burn sites or infected wounds * esophageal cancer or pancreatic cancer * life expectancy of less than 6 months as assessed by attending physician

Keywords: anorexia cachexia cancer unintentional weigh loss gastrointestinal tract adults